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A b s t r a c t  
Malaria remains a tremendous health burden in tropical areas, causing a life-threatening disease 
and accounts for 1 to 2 million deaths round the globe yearly. Researchers have explored different 
novel approaches to deliver and improve the biopharmaceutical performance of drugs used in 
malaria chemotherapy. These novel drug delivery systems (NDDS) enhanced bioavailability of these 
drugs and also may offer controlled release of these drugs. The major aim of the NDDS is to 
improve the efficacy of these drugs, and at the same time to eliminate their toxicity. These NDDS 
include: micro/nanoparticulate DDS, emulsion based DDS, dendrimers and liposomes among 
others. The development of these particulate carriers as vehicles for the delivery of active 
compounds is a novel area of research that provides a new hope in malarial chemotherapy. The 
work presents various trends in malarial chemotherapy, as well as an exhaustive screening of 
different particulate drug delivery systems (PDDS) and the recent advances in the delivery of anti-
malarial drugs using the novel particulate drug delivery systems (NPDDS). 








In recent years, there has been an upsurge in interest in the 
development of particulate drug delivery systems (PDDS) among 
researchers who are actively involved in drug delivery. This high 
interest is largely due to the potential of these systems to improve 
the biopharmaceutical performance of drug entities employed in 
disease therapy compared to conventional systems such as 
tablets, capsules and others. Designing and formulating these 
PDDS such as niosomes, liposomes, dendrimers, microparticles, 
nanoparticles, for the delivery of actives have proven to be 
challenging especially considering the vast formulation excipients 
needed and their cost implications. These challenges 
notwithstanding, formulation scientists have successfully designed, 
formulated and patented many particulate drug products for 
therapeutics and diagnostics (theranostics) purposes. Some of 
these products already in the market for clinical use are listed in 
table 1 
The development of these particulate carriers as vehicles for the 
delivery of active compounds is a novel area of research that  
provides with a new hope, the technology leading to the creation of 
devices and delivery systems with fundamentally new properties 
and functions. PDDS are designed and formulated by the 
incorporation of the drug compound into inert lipid vehicles 
containing surfactants and co-surfactants [1]. These particulate 
carriers offer a number of advantages making them ideal drug 
delivery systems. The advantages include: 
Better drug delivery profile across physiological barriers and 
membranes of the bodyDue to their small size, chemistry and 
distribution, they have bridged the gaps between structure and 
function of biomoleculesTheir micron and sub-micron size ranges 
enable them to be good potential carriers of biological molecules 
such as proteins, vaccines and other peptides 
They are used to target drug compounds to body tissues and sites 
with reduced or no untoward effectsThey increase drug 
solubilization especially practically insoluble drugs, and hence 
solve their bioavailability problemsTargeted delivery of drugs using 
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Table 1.Some particulate drug formulations available in the market 
 





Rapamune® Rapamycin Nanoparticles Oral Immunosuppressant Wyeth Pharma, USA
Intelectol® Vinpocetine Liposomes Oral Cerebrovascular disorders Menory Secret Inc., USA
Nurofen® Ibuprofen Nanocapsules Oral NSAIDs Abbott AG, USA
Lipofen® Fenofibrate Liposomes Oral Hypercholesterolemia Kowa Pharma Inc., USA
Ambisome® Amphotericin B Liposome Intravenous Infusion Fungal Infections Astellas Pharma Inc., USA
Mevacor® Lovastatin SLNs Oral Hyperlipidaemia Merck and Co. Inc., USA
Procardia® Nifedipine Nanosuspension Oral Hypertension Pfizer Labs Inc., USA
Cesol® Praziquantel SLNs Oral Antihelmintic Merck KGaA, Germany




Liposomes Oral Tumour Inhibition Valeant Pharma. Intl, USA
Note: SLNs - Solid Lipid Nanoparticles 
 
It is very interesting to note that the majority of the PDDS 
formulated are lipid- and/or polymer-based systems. Lipid-based 
formulations have been shown to enhance the bioavailability of 
drugs, especially drugs administered orally [3-6]. Lipid-based 
formulations can be used to influence the absorption of active 
ingredients through different mechanisms to modify the release of 
active ingredients thus, improving bioavailability. They can affect 
the intestinal environment, stimulate the lymphatic transport of 
active ingredients, and interact with enterocyte based transport [7]. 
The proven safety (biocompatibility) of lipid based carriers makes 
them attractive candidates for the formulation of pharmaceuticals. 
For poorly water soluble drug molecules, whose dissolution in 
water is likely the limiting step of overall oral absorption, the 
primary role of ingested lipids and their lipolytic products is to 
impact the drug dissolution step by forming ă with bile components 
ă different colloidal particles, which are able to maintain a larger 
quantity of hydrophobic drugs in solution via micellar solubilization 
[8]. The primary mechanism of action which leads to improved 
bioavailability is usually avoidance or partial avoidance of slow 
dissolution process which limits the bioavailability of hydrophobic 
drugs from conventional solid dosage form [9].     
Drug development and formulation experience have very low 
success rates with regards to drugs that enter the market. These 
shortfalls are due to factors such as toxicity of the therapeutic 
compounds, poor solubility leading to lowered bioavailability and 
reduced efficacy. These challenges are even more important in 
poverty related diseases (PRDs) especially malaria, due to the high 
prevalence of resistance and patient non-compliance to available 
drugs used in malaria chemotherapy. 
Malaria 
A parasitic killer disease 
Malaria is a very prominent parasitic disease because of its 
immense global significance. Malaria is a life-threatening disease 
and accounts for 1 million to 2 million deaths round the globe every 
year [10]. Malaria is a major public health problem in several 
tropical countries causing about 500 million clinical cases 
especially in children and pregnant women. The severe and 
complicated stages have a mortality rate between 20 and 50 % 
[11]. The geographical extent and clinical severity of malaria is 
increasing across much of sub-saharan Africa [12]. Approximately 
80 % of malaria cases in Africa were in 13 countries and over half 
of them occurred in Nigeria, The Democratic Republic of Congo, 
Tanzania, Ethiopia and Kenya. Among the cases that occurred 
outside Africa, 80 % occurred in India, Myanmar, Bangladesh, 
Indonesia, Papua New Guinea and Pakistan [13]. In humans, 
malaria is caused by four distinct species of parasites viz: 
Plasmodium vivax, Plasmodium malariae, Plasmodium falciparum 
and Plasmodium ovale. Among these, the most severe malaria is 
caused by blood-borne apicomplexan parasite P. falciparum which 
is responsible for almost all the malaria-related deaths [14].  
The elimination of malaria is now considered a realistic goal 
because of good surveillance and high intervention coverage 
between 2000 and 2007 which have resulted in the reduction of 
malaria cases and deaths by 50 % or more in some countries and 
regions of African countries [15]. Existing treatments for malaria 
include a limited number of clinically effective anti-malarial agents 
such as chloroquine, amodiaquine, sulphadoxine and 
pyrimethamine, etc. However, the clinical utility of most of the anti-
malarial agents is hampered due to problems such as poor oral 
bioavailability and the emergence of drug-resistant parasite strains. 
The coincidental proliferation of resistance to the commonly 
deployed first-line therapeutics poses a major threat to national and 
international targets to reduce child mortality due to malaria by 
one-third by the year 2015 [16]. In view of this, the entire world is 
looking for global expertise to improve the delivery and 
biopharmaceutical profiles of the current chemical entities deployed 
in malaria therapy worldwide, and especially in the endemic 
countries and regions. This would go a long way to cut down the 
high mortality rate associated with malaria. 
 
Chemotherapy of malaria 
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Currently, there is no patented, approved and clinically effective 
vaccine for use in the fight against malaria although committed 
efforts are being put in place to find one. Against this backdrop, 
chemotherapy is the mainstay of malaria treatment. Effective 
utilization of anti-malarial drugs have produced good results in the 
past since the clinical use of the majority of them has been reduced 
due to problems such as poor oral bioavailability and the 
emergence of drug-resistant parasite strains. 
Chloroquine (CQ) was one of the most useful drugs ever 
discovered [17]. CQ has several pharmacokinetic and 
pharmacological advantages over all the other anti-malarial drugs, 
which accounts for its excellent performance over eight decades of 
malaria therapy [18-20]. The main advantages of CQ therapy are 
the fast action in blood parasite stages, low toxicity, and good 
bioavailability from oral dosage form, water solubility, and high 
volume of distribution in the body [18-21]. Above all, CQ is cheap, 
relatively safe, easy to administer and was extremely effective. 
Wide use of CQ after the 1960s resulted in a wide decline of death 
among infants by 18 % compared to the pre-1960s [18, 21, 22]. 
This continued until the emergence of CQ resistance in the late 
1980s, which cause is still being studied, but non-compliance to 
drug regimen being the major pointer. The decline in CQ efficacy 
led to the introduction of Sulphadoxine-Pyrimethamine (SP) as the 
recommended first-line drug for uncomplicated malaria in several 
countries [23]. SP is a convenient single dose drug and within the 
same price range as CQ. However, the useful therapeutic life of SP 
has been shown to be short with reported treatment failure rates as 
high as 40 % after only a few years of widespread use and 
frequent adverse effects to the drug [18, 24]. Second and third line 
treatment are Amodiaquine (AQ) and Quinine (QN) [25]. QN is the 
drug of choice for complicated malaria such as cerebral malaria but 
resistance to the drug has been widely reported and also the drug 
produces high toxicity when administered intravenously. Another 
drug of choice is primaquine (PQ) which is characterized by poor 
oral bioavailability and drug related side effects (SEs) that can lead 
to haemolytic anaemia, gastrointestinal disturbances, heart failure 




Quinine         
                   
 
                                              Chloroquine 
 
Figure 1: Some of the Aminoquinoline compounds used in malaria 
treatment [27, 28] 
 
Resistance to these drugs by the Plasmodium strains, and the high 
toxicity effects associated with them has reduced the popularity of 
these drugs in malaria treatment. This has led to the need to 
device new methods of malaria therapy and the search for the 
most effective drugs, and/or drug combinations that would reduce 
morbidity and mortality of the disease. 
Current trend in the treatment of malaria 
In 1967, the government of the PeopleÊs Republic of China 
embarked on a systematic examination of indigenous plants used 
in traditional remedies as sources of drugs. One such plant, a 
pervasive weed with a long history of use is known as qing hao 
(Artemisia annua L., sweet wormwood, annual wormwood) [29, 
30]. Artemisinin (ART) is proven to be a sesquiterpene, a natural 
product composed of fifteen carbon atoms based on three isoprene 
molecules usually joined head-to-tail, with additional oxygen atom 
functionality. The really striking feature of ART was the peroxide 
bridge spanning one of the moleculeÊs rings, which was shown to 
be its active ingredient, responsible for its activity against 
plasmodium [31].  
The artemisinins including artesunate (AS), artemether (ARM), 
arteether (AE) and dihydroartemisinin (DHA) are the most effective 
anti-malarial drugs known today. They possess a remarkably wide 
therapeutic index. They have the ability to rapidly kill a broad range 
of asexual parasite stages at safe concentrations that are 
consistently achievable through standard dosing regimens [13]. 
ART and its derivatives are considered the keystones of the 
treatment of P. falciparum malaria due to their high potency and 
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Figure 2:  Artemisinin and its derivatives [29 and 31]. 
 
rapid action [32]. They have gametocytocidal properties by 
inhibiting parasite transmission which probably reduces the 
development of resistance [33]. Despite these achievements, there 
are reported cases of in vitro tolerance in South America [34], and 
in South-East Asia [18, 35]. Furthermore, stable resistance to ART 
drugs has been achieved independently in two different rodent 
malaria models [36, 37]. To minimize resistance, the World Health 
Organization, WHO has recommended ART to be used to treat 
uncomplicated malaria in combination with other anti-malarial 
drugs in the so-called artemisinin-based combination therapy 
(ACT). With their deployment in 2005 and 2006 as first-line 
treatments in several endemic countries of the world, morbidity and 
mortality associated with malaria decreased [38, 18]. However, 
major limitations of ACTs have been ascribed to the imbalance 
between demand and supply, comparatively high cost, dosing 
complexity and the lack of clinical experience. There are also 
physicochemical and biopharmaceutical problems of the 
artemisinins (ARTs) such as short half-life, poor oral bioavailability 
and low solubility [39]. Furthermore, the reported advances 
recorded by the ACTs are now being threatened by low sensitivity 
of the parasites to ACTs in South-East Asia [40, 17, 18]. 
Against these backdrops, there is an urgent need to develop highly 
efficacious formulations of the ARTs, and especially the ACTs, to 
enhance their oral solubility and pharmacokinetic profiles. This 
would reduce the high trend of malaria morbidity and mortality, and 
save the world from the catastrophe of non-availability of highly 
efficacious ACT formulations to combat this deadly parasitic 
disease. 
Particulate drug carriers in malaria 
chemotherapy 
Due to lack of economic incentives, there are not many initiatives 
for the development of new anti-malarial agents. This situation led 
to the smart and effective utilization of the current anti-malarial 
agents with the help of novel drug delivery systems (NDDS) [14]. 
The main goal of malaria therapy is to promote a high drug 
concentration in the intracellular parasitophorous vacuoles where 
the plasmodium is hosted [13]. Thus, the major setbacks of 
conventional malaria chemotherapy is the development of multiple 
drug resistance and the non-specific localization to intracellular 
parasites, resulting in high dose requirements and subsequent 
intolerable side effects which eventually lead to patient non-
compliance [26, 13]. Hence, to improve the delivery of anti-
malarials drugs researchers have developed and evaluated many 
particulate drug carriers which are mainly lipid-based (e.g. 
liposomes, nanoparticles, microparticles), and polymer-based (e.g. 
dendrimers and nanocapsules) [14]. These drug carriers are known 
to improve the efficacy of currently available anti-malarial drugs 
and also contribute to the formulation and delivery of new chemical 
entities. Drug targeting might have great advantage in malaria 
since malaria parasites frequently develop drug resistance due to 
the administration of drugs in concentrations which might be low in 
the presence of a high parasite load. Furthermore, particulate drug 
carriers have the potential to restore the use of old and toxic drugs 
by modifying their biodistribution, improve their bioavailability and 
reduce their toxicity [13, 18]. These advantages are of immense 
importance to malaria chemotherapy, since the development of 
new dosage forms for delivering drugs to parasite infected cells is 
urgently needed, especially for the anti-malarials in clinical use [41, 
18]. 
 
Particulate Drug Delivery Systems (PDDS) used in 
malaria 
Early treatment with effective anti-malarial drugs is the main life-
saving intervention in malaria therapy. PDDS such as liposomes 
and nanoparticles have been studied for intracellular infections 
because they are able to deliver the drug to the specific target in 
the human body, where the parasite is located, such as tissues 
(spleen and liver) and cells (macrophages and kupffer cells)[42-
44]. Some of these particulate systems applied in the  
delivery of anti-malarial drugs will be discussed below. 
 
Liposome systems as anti-malarial carriers 
Liposomes, first described in 1976, were the first type of particulate 
drug delivery system applied in disease therapy [45, 18]. These are 
self-assembling spherical, closed colloidal structures composed of 
phospholipid bilayers that surround a central aqueous space. 
These amphiphilic phospholipid molecules form a closed bilayer 
sphere, shielding the hydrophobic groups from the aqueous 
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environment, while maintaining contact with the aqueous phase 
through the hydrophilic head groups [46, 18]. Liposomes are 
classified into three basic types based on their size and number of 
bilayers. Multilamellar vesicles (MLVs) consist of several lipid 
bilayers separated from one another by aqueous spaces. These 
entities are heterogeneous in size, often ranging from a few 
hundred to thousands of nanometers in diameter. On the other 
hand, both small unilamellar vesicles (SUVs) and large unilamellar 
vesicles (LUVs) consist of a single bilayer surrounding the 
entrapped aqueous space. SUVs are less than 100 nm in size 
whereas LUVs have diameters larger than 100 nm [47, 48]. The 
predominant physical and chemical properties of a liposome are 
based on the net properties of the constituent phospholipids, 
including permeability, charge density and stearic hindrance. Drug 
loading into liposomes can be achieved through: 
Liposome formation in an aqueous solution saturated with 
soluble drug 
The use of organic solvents and solvent exchange mechanisms 
The use of lipophilic drugs 
pH gradient methods [49] 
Liposomes have been widely reported to be used for drug delivery 
and drug targeting [51-53]. Some biologically active compounds 
have been encapsulated using liposomes [54, 55]. It has also been 
reported by Allison et al [56] and Alving et al [57] to be used as 
immunological adjuvants in vaccination.  
Anti-malarial drugs such as Chloroquine (CQ), Quinine (QN), 
Primaquine (PQ), Artesunate (AS), Artemether (ARM), Arteether 
(AE) and very recently, a combination of Artemisinin (ART) and 
curcumin have been encapsulated in neutral conventional or long-
circulating liposomes using different preparation techniques [58-
65]. From the findings of these studies, the pH gradient technique 
seems to be the best for enhancing the encapsulation efficiency of 
anti-malarials. Investigations into the possibility of encapsulating 
drugs like QN and CQ in neutral large unilamellar vesicles (LUVs) 
applying the pH gradient method have been concluded and 
reported [58, 59, 13]. In the study, uptake of 148 and 104 
nmol/ømol were reported 
 
Figure 3: Schematic representation of a liposome [50] 
after 15 min, and 81 and 88 nmol/ømol were also reported after 2 h 
for QN and CQ respectively. This finding showed that drugs such 
as QN and CQ were able to accumulate within these LUVs which 
exhibit a proton gradient. Bayomi et al, encapsulated AE for oral 
administration in neutral multilamellar liposomes [64]. In their study, 
multilamellar liposomes prepared with 
dibehenoylphosphatidylcholine (DBPC), cholesterol (CHOL) and 
AE at a ratio of 1:1:2 presented a mean size of 3.20 μ 1.03 øm and 
entrapment efficiency (EE) of 82.3 %. The daily release rate of AE 
from liposomes prepared with mixtures of DBPC and 
dipalmitoylphosphatidylcholine (DPPC) at a ratio of 1:1 was 0.818 
%/day while it was 0.783 %/day when CHOL was added to DBPC 
at a ratio of 1:1, and 0.616 % when CHOL was used at a ratio of 
1:2. These findings showed that the increase in the length of acyl 
chain of phospholipids as well as the addition of CHOL led to a 
decrease in the release rate of AE. This might be due to the ability 
of CHOL to induce drug/phospholipid interactions in the bilayer, 
leading to a decrease in drug release. Its in vivo evaluation 
compared with that of an oral aqueous suspension showed that 
orally administered liposomes of AE gave a relative bioavailability 
of 97.91 % while its oral aqueous suspension gave 31.83 %. This 
is shown in fig. 5. Gabriels and Plaizier-Vercammen have reported 
the encapsulation of AS in neutral liposomes using a pH 5 buffer 
solution as aqueous phase to prevent the aqueous instability of AS 
[62]. The EE of the AS-loaded liposomes was approximately 100 % 
and the liposomes remained stable for 10 days at 25 ÀC. They 
reported that the release of the drug from the liposomes was 
influenced by the lipid content as the release rate decreased with 
increase in lipid concentration.  
Furthermore, Chimanuka et al. reported the encapsulation of β-
artemether (βAM) in neutral liposomes, and also evaluated its 
therapeutic efficacy in mice infected with Plasmodium chabaudi 
[63]. They reported an EE of about 100 % for their formulations, 
which also retained their stability for 3 months at 4 ÀC. When 
administered to the infected mice, a 100 % cure was observed 
after 22 days of infection. Benedetta et al. reported the 
encapsulation of ART and a combination of ART and curcumin in 
conventional and PEGylated liposomes using the film hydration 
method [65]. In the study, ART conventional liposomes (A-CL) 
were formulated using Phospholipon® 90G (P90G), CHOL and 
ART. ART-loaded PEGylated liposomes (A-PL) were formulated 
using polyethyleneglycol-2000-distearoylphosphatidylethanolamine 
(PEG2000-DSPE), P90G, CHOL and ART. ART-Curcumin-loaded 
conventional liposomes (AC-CL) were formulated using P90G, 
CHOL, ART and curcumin while ART-Curcumin-loaded PEGylated 
liposomes (AC-PL) were formulated using PEG2000-DSPE, P90G, 
CHOL, ART and Curcumin. They reported that the mean diameter 
of all the ART-based vesicles was ª 200 nm and suitable for 
intraperitoneal administration. HPLC analysis of the vesicles gave 
EE of 78 % and 68 % for conventional liposomes and PEGylated 
liposomes respectively. The EE of curcumin showed that the EE for 
AC-PL was smaller than that of AC-CL. This could be due to the 
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Figure 4: Mean plasma concentration versus time profile of oral  
arteether liposomes and its aqueous suspension [64] 
 
smaller size of PEGylated liposomes which decreases the bilayer 
capacity of solubilizing lipophilic drugs. All the ART-loaded vesicles 
remained stable for a period of 1 month. When the ART-loaded 
vesicles were administered in mice infected with Plasmodium 
berghei, parasitaemia was reduced faster with AC-PL to about 60 
% after only 3 days. In all liposomal treatments, parasitaemia was 
reduced more than 95 % from day 5. Interestingly, the infection 
was almost totally reverted in mice treated with A-CL after 7 days 
and with AC-CL, A-PL and AC-PL after 5 days. This is as shown in 
table 2. 
On the basis of the above studies, liposomes have been 
extensively used as an effective carrier of anti-malarial drugs in the 
treatment of experimental malaria. This could be explained from 
their ability to reduce the toxicity profile of these chemical entities, 
show improved experimental therapeutic efficacy against the 
Plasmodium strains, modify the bioavailability of these drugs as 
well as ensure prolonged in vivo release. 
Table 2. Percentage reduction of parasitaemia in P. berghei 

















3 67.39 60.86 35.86 11.95 22.82 60.86
5 100.00 37.68 96.01 98.84 97.39 97.24
7 94.79 80.59 99.49 98.79 97.04 98.05
9 96.47 51.94 100.00 98.68 98.26 95.61
12 99.02 90.92 98.36 98.95 93.73 99.00
Notes: A: ART, A-CL: ART conventional liposomes, A-PL: ART-
loaded PEGylated liposomes, AC-CL: ART-Curcumin-loaded 
conventional liposomes, AC-PL: ART-Curcumin-loaded PEGylated 
liposomes 
 
Nanocarriers for anti-malarial drug delivery 
Nanotechnology-based drug delivery systems for malaria have 
been evaluated since they are able to deliver the drug to the 
specific target in the human body where the malaria parasite is 
located. Some of these novel drug delivery systems (NDDS) could 
be used for both the active and passive targeting of the anti-
malarials to the site where the parasite is located. Conventional 
nanocarriers such as liposomes, polymeric nanoparticles, and 
surface-modified long-circulating nanocarriers like 
polyethyleneglycol (PEG)-coated particles, could be employed in 
passive targeting [66, 13]. Nanocarriers are useful tools to improve 
the pharmacokinetic profile of effective drugs that have limited 
pharmacotherapeutic application due to high toxicity, low 
bioavailability and poor water solubility [67-69]. The major objective 
in using nanocarriers as drug delivery systems (DDS) is to promote 
drug or vaccine protection against extracellular degradation, to 
improve selectivity in relation to the target, to reduce the frequency 
of administration and the duration of the treatment and to improve 
the pharmacokinetic profile of the drug [68, 70, 71, 13]. The most 
important property of a nanocarrier in malaria therapy is the ability 
to remain in the blood stream for a long period of time in order to 
improve the interaction with infected red blood cells (RBCs) and 
parasite membranes, protection of unstable drugs, cell-adhesion 
properties, and the ability to be surface-modified by conjugation of 
specific ligands [72, 73, 13]. 
Lipid nanocarriers such as nanostructured lipid carriers (NLC) have 
been reported to be very effective and efficient for the parenteral 
delivery of artemether (ARM) [74]. NLC are lipid nanocarriers 
based on the mixture of biocompatible solid lipid and liquid lipid 
(oil). They are very good alternatives to liposomes and 
nanoemulsions due to their ease of manufacture, particulate 
nature, high drug loading and ability to sustain the release of the 
drug [75]. Also, the aqueous nature of NLC, their nanostructure 
and the biocompatibility of the excipients would enable intravenous 
delivery of active drugs with concomitant reduction or abolishment 
of pain on injection. Furthermore, their ability to sustain the delivery 
of therapeutic agents could be useful in combating the 
recrudescence which is commonly observed with ARM therapy 
[76]. Joshi et al. formulated NLC of ARM and tested it in vivo using 
P. berghei infected-mice [74]. The NLC prepared by the 
microemulsion template technique [77] using mixtures of the lipids 
and surfactants had an average particle size of 63 μ 28 nm, while 
the EE was 30 μ 2 %. This result indicated that the encapsulated 
drug would be released in a sustained manner which may help to 
prevent recrudescence. The in vivo studies clearly demonstrated 
that both administered doses of the nanoject, ND I and ND II 
(Nanoject Dose I and II), were significantly more effective 
compared to the marketed formulation (Larither®). ND I showed 
very quick onset of action (~95 % anti-malarial activity) compared 
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to the marketed formulation (~45 % anti-malarial activity) on the 8th 
day.  
Very recently, Yameogo et al. reported the intravenous delivery of 
artemisinin (ART) using self-assembled bio-transesterified 
cyclodextrin (CD)-based nanocarriers [78]. The carriers were used 
to deliver ART due to their size and ability to deliver lipophilic drugs 
appropriately. Their study was guided by the need to improve ART 
dosage by encapsulating it in CD esters-based nanocarriers, and 
to ensure a sufficient blood circulation time of the nanocarriers 
through their surface modification for targeted delivery to infected 
erythrocytes after systemic administration. However, in vitro study 
of ART-loaded nanocarriers against 3D7 (CQ-sensitive) and K1 
(CQ-resistant) strains of P. falciparum indicated that the ART-
loaded vesicles exhibited satisfactory in vitro activity against the 
different strains of P. falciparum. The findings suggested that 
neither additive nor antagonistic effect was observed when ART 
was nanoencapsulated in CD-based nanocarriers. 
Lipophilic anti-malarial drugs have also been delivered using 
nanocarriers in form of nanoemulsions. Singh and Vingkar reported 
that Primaquine (PQ) nanoemulsions have been delivered orally 
against P. berghei infected-wistar rats [79]. Nanoemulsions are 
heterogenous systems comprised of two immiscible liquids in 
which one liquid is dispersed as droplets in another liquid [80]. The 
ingredients of nanoemulsions are well tolerated by the body owing 
to their structural and functional similarity with physiological lipids 
[81, 82]. The idea behind their study was that since nanoemulsions 
are easily taken up by lipoprotein receptors in the liver, they can be 
exploited for the encapsulation of PQ for targeted delivery to the 
liver. Lipid nanoemulsion was prepared using Ovathin 160 (egg 
lecithin), Topcithin 300 (soyabean lecithin liquid) and PQ. The 
formulation gave an encapsulation efficiency, EE of 95 %, and an 
in vitro release > 90 % in phosphate buffer pH 7.4. On oral 
administration to rats at a dose of 1.5 mg/kg/d, the parasitaemia 
was completely cleared in the animals leading to increased survival 
time of the test animals than those receiving the plain drug 
solution. Thus, lipid nanoemulsion of PQ could achieve significant 
higher drug levels in the liver after oral administration. While in 
circulation, the lipid nanoemulsion associates with Apo E due to its 
narrow size (20 ă 200 nm), which would enhance the drug uptake 
by liver parenchymal cells, thereby leading to improved anti-
malarial activity. 
The above studies showed clearly that the fabrication of 
nanocarriers for the delivery of available anti-malarial drugs for the 
treatment of malaria (both CQ-sensitive and CQ-resistant) could be 
promising, and could serve as veritable alternative to enhance the 
pharmacokinetic and biodistribution performance of these drugs. 
These have rekindled the hope that malaria could be properly 
treated when antimalarial drugs are formulated and delivered in 
particulate nanocarriers, pending the discovery and availability of 
effective malaria vaccine for clinical use. 
 
Microparticulate carrier systems for anti-malarial drug 
delivery 
One of the novel systems for the enhanced delivery of anti-malarial 
drugs is the microparticulate systems, which might be in the form of 
microemulsion or microspheres. For some years now, lipid 
microemulsions have been designed and formulated as a 
commercially feasible NDDS with the capability to improve oral 
bioavailability and therapeutic efficacy of several drugs. These 
microcarriers are thermodynamically stable, transparent, isotropic, 
low viscosity colloidal dispersions consisting of microdomains of oil 
and/or water stabilized by an interfacial film of alternating 
surfactant and co-surfactant molecules [83]. Microspheres on the 
other hand, are characteristically free-flowing powders consisting of 
proteins or synthetic polymers which are biodegradable in nature 
and ideally having a particle size less than 200 øm [84]. Several 
anti-malarial drugs have been encapsulated into microcarrier 
systems. They include Halofantrine (Hf) [85] and Primaquine (PQ) 
[86, 14], however, they were not tested in vivo. Nishi and 
Jayakrishnan formulated PQ-conjugated gum Arabic microspheres 
using thermal denaturation process and dehydration which yielded 
as much as 75 % of PQ-loaded microspheres [86]. Thus, this 
formulation approach could be said to be reproducible. The 
microspheres were spherical, free-flowing with an average size 
below 2 øm. In vitro release of PQ from the microspheres in 
phosphate buffer system (PBS) at 37 ÀC showed that matrices 
having a higher degree of oxidized gum Arabic experienced slow 
release due to the better drug conjugation onto the polymer 
because of the large number of aldehyde groups present e.g. only 
100 % of PQ was released from 50 % oxidized matrix having a 
drug payload of 4.7 % while 30 % of drug was released from 20 % 
oxidized matrix with similar payload. Attama and Igbonekwu 
reported enhanced in vitro release of highly lipophilic drug Hf in 
three biorelevant media: simulated gastric fluid (SGF pH 1.2), 
simulated intestinal fluid (SIF pH 7.2) and phosphate buffer (pH 
6.8) [85]. The model drug, Hf at different concentrations was 
loaded into surface-modified solid lipid microspheres using lipid 
matrix formed from goat fat and the phospholipid, phospholipon® 
90H. The formulation gave discrete and spherical microspheres 
with particle size range of 33-34 øm and EE between 87 and 91 % 
after 3 months. The in vitro release showed sustained drug release 
from the lipid microspheres compared to the commercial drug, 
Halfan®. 
The importance of NDDS is to deliver drug entities in such a 
manner that their pharmacokinetic profile such as solubility and 
bioavailability would be enhanced. From the above reported 
experimental studies on the delivery of anti-malarial drugs using 
NDDS, it could be rightly stated that microparticulate systems 
formulated using polymeric and lipidic materials could be good 
alternative for the improved delivery of these drugs. However, 
these studies should be stretched further to elicit the possible 
mechanism of anti-malarial activity. Studies should also be done to 
encapsulate other available anti-malarial drugs used in the clinic for 
malaria chemotherapy. This would make it easier to determine 
formulations that could be taken up for possible clinical trials. 
Umeyor et al. International Journal of Drug Delivery 5 (1) 01-14 [2013] 
 
PAGE | 8 |
 
 
Dendrimers as nanoscopic carriers of anti-malarial 
drugs 
Dendrimers are globular repeatedly branched macromolecules that 
exhibit controlled patterns of branching with multiple arms 
extending from a central core. They are used in drug delivery and 
imaging at a size range of 10 to 100 nm in diameter, and have 
improved the pharmacokinetic and pharmacodynamic properties of 
encapsulated drug, making them less susceptible to uptake by the 
reticuloendothelial system (RES) [87, 88, 18]. Unique structures of 
dendrimers include highly branched and well-defined globular 
structures with controlled surface functionality, adding to their 
potential as new scaffolds for drug delivery [89, 90]. Some 
dendrimers are formulated by incorporating carbohydrates in their 
structures. These glycodendrimers are of immense benefit for drug 
encapsulation and delivery. They can be classified basically as 
carbohydrate-coated, carbohydrate-centered and carbohydrate-
based [91].  
 
 
Figure 5 : Schematic representation of a Dendrimer [92] 
 
Bhadra et al. have reported the formulation of glycodendrimers for 
hepatic targeting of PQ phosphate [91]. The glycodendrimers were 
obtained by the formulation of polypropyleneimine (PPI) 
dendrimers with ethylenediamine (ED) as the core coating it with 
galactose, and finally loading the drug by the equilibrium dialysis 
method. The haemolytic toxicity study of the dendrimers showed 
that carbohydrate coating drastically reduced the haemolysis of 
RBCs, which is a major limitation in the use of polycationic 
dendrimers in drug delivery. The reduction was due to covering of 
the cationic amine terminations responsible for haemolysis with 
carbohydrates. The biodistribution study (BDS) showed compared 
to 2.3 %, 1.5 % and 18.5 % of the free PQ found in the liver, spleen 
and blood after 2 h, carbohydrate coated PPI PQ dendrimers gave 
50.7 %, 5.5 % and 7.8 % of the drug in the liver, spleen and blood 
after 2 h of administration. This significant delivery of PQ in the 
liver might be due to galactose coating because galactose 
receptors are found in the liver, which localized the coated systems 
and ensured sustained release of the drug from the dendrimers up 
to 2 h. In another study, CQ was loaded in PEGylated-poly-lysine 
type of dendrimers for sustained and controlled delivery of the drug 
through intravenous route of administration [93]. In that study, there 
was also a significant reduction in the in vitro levels of the 
trophozoite stages of P. falciparum when treated with the 
PEGylated-poly-lysine based dendrimers. When evaluated in vivo 
using albino rats, the system controlled and prolonged the blood 
levels of CQ in the rats after intravenous administration. From their 
study, the PEGylated dendrimers are also suitable for use as a 
safe and effective carrier for intravenous administration of CQ. 
Furthermore, ARM, an ART derivative was encapsulated in a 
PEGylated-lysine based copolymeric dendritic micelles for 
solubilization and delivery of ARM [94]. Transmission Electron 
Microscopy (TEM) of the dendrimers showed formulations in 
nanometric size range (5-25 nm), spherical and uniform shaped. 
Experimental in vitro release studies gave significant (p<0.05) 
release rates for the 5000D and 2000 D series respectively, but 
with the 5000 D series been slightly higher. This higher drug 
release might be due to the lower weight fraction of hydrophobic 
core in these polymers. This study showed that PEGylated-lysine 
Umeyor et al. International Journal of Drug Delivery 5 (1) 01-14 [2013] 
 
PAGE | 9 |
 
 
dendrimer systems could act as effective nanocarriers of anti-
malarials. 
These studies are very promising and have the potential of creating 
new dimensions in the use of anti-malarials chemotherapy, 
however more anti-malarial drugs should be encapsulated using 
dendrimers, especially the ACTs. 
 
Self-emulsifying carrier systems for anti-malarials 
Self-emulsifying drug delivery systems (SEDDS) have gained 
significant interest due to their ability to increase solubility and 
bioavailability of poorly soluble drugs. SEDDS have been 
described as homogenous mixtures of natural or synthetic oils, 
solid or liquid surfactants, or alternatively, one or more hydrophilic 
solvents and co-solvents [95-98]. The principal characteristic of 
these systems is their ability to form fine oil-in-water (o/w) 
emulsions or microemulsions upon mild agitation following dilution 
by aqueous phases. This property renders SEDDS as good 
candidates for the oral delivery of lipophilic drugs with adequate 
solubility in oil or oil/surfactants blends. SEDDS can be 
administered in soft or hard gelatin capsules, and will produce fine 
oil droplets/micelle dispersion upon capsule disintegration and 
aqueous dilution. Self emulsifying/dispersing formulations spread 
readily in the GIT, while the digested motility of the stomach and 
intestine provide the agitation necessary for self-
emulsification/dispersion [99]. SEDDS formulations are 
characterized by in vitro lipid droplet sizes of 100 nm and above, 
and the dispersion has a turbid appearance [100]. The potential 
benefits of the use of SEDDS and self-microemulsifying drug 
delivery systems (SMEDDS) for improving the extent and 
reproducibility of the oral absorption of anti-malarial drugs have 
been reported.  
Furthermore, a solid microemulsion pre-concentrate formulation 
loaded with artemether (ARM) known as NanOsorb, was recently 
formulated by Joshi et al. and its anti-malarial activity was 
evaluated in P. berghei (ANKA strain) infected-mice, and also 
compared with the activity of the marketed formulation of ARM 
(Larither®) and ARM solution [14]. ARM-NanOsorb system were 
formulated using the required amounts of surfactants, Gelucire 
44/14® (Lauroyl macrogol glycerides) + Labrasol® (Caprylocaproyl 
macrogol-8-glycerides), and oil, capmul® MCM (Glyceryl mono-, di-
caprylate) in the ratio of 3:2 after a formulation development study 
using the pseudo-ternary phase diagram. The in vivo anti-malarial 
study showed that ARM-NanOsorb system has an activity 2.6-fold 
and 2.3-fold higher than that of ARM solution and Larither® 
respectively. This clearly demonstrated the effectiveness of the 
microemulsion system in improving the therapeutic efficacy of 
ARM, and the animals treated with NanOsorb-ARM showed higher 
survival rate than that of ARM solution and Larither®.  
This higher anti-malarial activity of the NanOsorb-ARM is a 
combined result of the nanosize (183 nm) of the microemulsion 
instantaneous dissolution of ARM which would facilitate quick 
 
Figure. 6: Anti-malarial activity of the various ARM formulations. 
(*) indicates significantly (p<0.05) higher than ARM solution and 
Larither® [14]. Note: ARM-Artemether. 
 
absorption, probable enhancement in bioavailability due to lipidic 
nature of the drug and protection of ARM from the acidic 
environment of the stomach. The bioavailability of Hf has been 
evaluated in beagle dogs using SEDDS and SMEDDS [101]. The 
particle sizes of the SMEDDS and SEDDS were 50 nm and 100 ă 
200 nm respectively. After administration to the dogs, the mean 
absolute bioavailability of Hf for all formulations administered 
ranged between 52 and 67 % representing approximately 6-to 8-
fold improvement compared to the 8.6 μ 3 % bioavailability 
obtained from the commercial tablet formulation. The ability of the 
lipid-based formulations to deliver Hf in a solubilised and dispersed 
manner resulted in significant improvements in the bioavailability of 
Hf.  Mandawgade et al. formulated SMEDDS-loaded with β-
Artemether (βAM) using a natural lipophile or natural long chain 
triglyceride (N-LCT) [102]. N-LCT is a refined vegetable oil 
obtained from pressed fruit seed kernel; an edible oil with 
1:2.37:1.36 ratio of saturated fatty acid (SFA), monounsaturated 
fatty acid (MUFA), polyunsaturated fatty acid (PUFA), and 
triglycerides of C16-C18 fatty acids. The concept of this formulation 
and trial was that upon oral administration of the SMEDDS, they 
rapidly transform into microemulsions (MEs). The formulation was 
tested in P. berghei infected-mice and the results compared with 
that of the commercial brand, Larither®. In vivo results showed that 
there was very significant (p < 0.05) improvement in the anti-
malarial activity of SMEDDS-loaded βAM against the lethal ANKA 
strain of P. berghei with an average parasitaemia of 35.11 μ 4.16 
on day 20 of infection compared to Larither® with an average 
parasitaemia of 42.35 μ 4.18. To the best of our knowledge, the 
only particulate carrier system reported for the encapsulation of an 
ACT for experimental treatment of malaria was the one designed 
and developed by Kuentz et al. in collaboration with 
GlaxoSmithKline (GSK), UNICEF, the World Bank, Medicines for 
Malaria Venture and the WHO [103]. They formulated SEDDS-
loaded with Chlorproguanil + Dapsone + Artesunate (CDA). After 
oral administration in rats, the self-emulsifying systems enhanced 
the bioavailability of the chemical entities, and proved promising in 
experimental treatment of malaria. 
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These studies have shown, interestingly, the potential of self-
emulsifying systems to improve the oral solubility and bioavailability 
of lipophilic drugs. More anti-malarial drugs should be 
encapsulated and evaluated using this drug delivery system (DDS). 
However, to the best of our knowledge, no study have reported the 
encapsulation and delivery of anti-malarial drugs using self-
nanoemulsifying drug delivery systems (SNEDDS) or solid-
SNEDDS (s-SNEDDS) for the improvement of the bioavailability of 
these drugs, especially the combined therapy as in ACTs against 
experimental malaria. The results from the reported PDDS are very 
promising especially in the continued effort to halt resistance of 
plasmodium strains to available anti-malarial drugs until an 
effective malarial vaccine is discovered. However, further studies 
should be extended into determining the possible or exact 
mechanisms of action of these PDDS when used to encapsulate 
anti-malarial drugs so that it would be easier to solve any untoward 
effect(s) that might occur especially when possible clinical trials of 
the most promising of these formulations would be commenced. 
Conclusion 
PDDS could be the future of malarial chemotherapy. This is 
because of the numerous opportunities it could provide for 
improving the efficacy of the current anti-malarial drugs used in 
malaria therapy, as well as possible new drugs characterized by 
poor solubility, bioavailability and high toxicity profile. There is 
urgent need to try possible modifications of the properties of 
already reported carrier systems so as to enhance their 
encapsulation and delivery properties. ACTs also have not been 
widely featured in the various studies reported. Since the WHO 
standard for malaria chemotherapy is the use of the ACTs, they 
should be extensively studied using any of the PDDS. Furthermore, 
the use of formulation excipients, especially natural materials that 
could be easily sourced from a particular locality should be 
encouraged. This would help to reduce the cost of formulation 
design and development, reduce or eliminate any possible 
untoward effect(s) that might result from the use of highly synthetic 
excipients, thereby leading to the development of smart, well-
tolerated, cost effective and efficacious therapeutic particulate 
carrier systems for targeted delivery to treat malaria in the clinics. 
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